Vapotherm (VAPO)
(Delayed Data from OTC)
$1.25 USD
-0.01 (-0.51%)
Updated Apr 26, 2024 03:42 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
VAPO 1.25 -0.01(-0.51%)
Will VAPO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VAPO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VAPO
Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates
Vapotherm (VAPO) Reports Q1 Loss, Lags Revenue Estimates
VAPO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates
Analysts Estimate PetIQ (PETQ) to Report a Decline in Earnings: What to Look Out for
Earnings Preview: Vapotherm (VAPO) Q4 Earnings Expected to Decline
Other News for VAPO
Vapotherm Secures New $4 Million Senior Secured Loan
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market